The FDA has cleared AbbVie’s next-generation dopamine therapy for Parkinson’s disease, tavapadon, which will be marketed as Juvmo. The regulator’s approval reflects a shift toward dopamine agonist options designed to match the symptom relief of earlier agents while aiming for fewer side effects. For Parkinson’s treatment, the approval adds another branded platform in a heavily competitive neurodegenerative market, where differentiation often hinges on tolerability and patient adherence as much as efficacy. The move also signals continued regulatory attention to Parkinson’s symptom management drugs, even as disease-modifying programs remain in active development across the field.